Hyaluronic Acid-modified Cationic Nanoparticles Overcome Enzyme CYP1B1-mediated Breast Cancer Multidrug Resistance

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2019 Jan 30

PMID 30694105

Citations 12

Authors

Jun Zhang

Jia Song

Xiao Liang

Yunzhi Yin

Tiantian Zuo

Daijie Chen

Qi Shen

Affiliations

Soon will be listed here.

Abstract

Aim: Enzyme CYP1B1 (CYP1B1) is usually overexpressed in multidrug resistance (MDR) breast cancer cells, which could metabolically inactivate docetaxel (DTX).

Materials & Methods: The cationic core-shell nanoparticles (hyaluronic acid/polyethyleneimine nanoparticles [HA/PEI NPs]) modified with hyaluronic acid (HA) were developed and coloaded with DTX and α-napthtoflavone (ANF, a CYP1B1 inhibitor) to overcome MDR in breast cancer induced by CYP1B1. Physicochemical characterization, MDR reversing effect in vitro and pharmacokinetics in vivo of HA/PEI NPs were evaluated.

Results: The HA/PEI NPs exhibited spherical morphology with size of (193.6 ± 3.1) nm. The HA/PEI NPs could reverse MDR effectively by downregulating the expression of CYP1B1. The HA/PEI NPs improved the bioavailability of DTX.

Conclusion: The HA/PEI NPs might be a promising strategy to overcome CYP1B1-mediated breast cancer MDR.

Citing Articles

Protease-activated indocyanine green nanoprobes for intraoperative NIR fluorescence imaging of primary tumors.

Lew B, George M, Blair S, Zhu Z, Liang Z, Ludwig J Nanoscale Adv. 2022; 4(19):4041-4050.

PMID: 36285222 PMC: 9514568. DOI: 10.1039/d2na00276k.

Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.

Narendra G, Choudhary S, Raju B, Verma H, Silakari O Clin Pharmacokinet. 2022; 61(11):1495-1517.

PMID: 36180817 DOI: 10.1007/s40262-022-01174-7.

Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances.

Jia Y, Chen S, Wang C, Sun T, Yang L Front Bioeng Biotechnol. 2022; 10:990145.

PMID: 36091467 PMC: 9449492. DOI: 10.3389/fbioe.2022.990145.

Antimicrobial Peptides and Cationic Nanoparticles: A Broad-Spectrum Weapon to Fight Multi-Drug Resistance Not Only in Bacteria.

Valenti G, Alfei S, Caviglia D, Domenicotti C, Marengo B Int J Mol Sci. 2022; 23(11).

PMID: 35682787 PMC: 9181033. DOI: 10.3390/ijms23116108.

Nanocarriers for anticancer drugs: Challenges and perspectives.

Alqosaibi A Saudi J Biol Sci. 2022; 29(6):103298.

PMID: 35645591 PMC: 9130109. DOI: 10.1016/j.sjbs.2022.103298.